AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP announced it is investigating ArriVent BioPharma (NASDAQ: AVBP) for potential securities-law violations, soliciting investors with losses over $100,000. The investigation follows the company's October 6 disclosure that its Phase 3 FURVENT trial of firmonertinib missed statistical significance on its primary endpoint, sending shares sharply lower.
Key figures
- Drug Name
- firmonertinib
- Phase Of Trial
- Phase 3
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.